New guidance published by the National Institute for Health and Care Excellence (NICE) says that another potentially life-extending drug combination for some who suffer from advanced breast cancer will now be available on the Cancer Drugs Fund (CDF).
The draft guidance recommends Ribociclib, also known as Kisqali, which is made by Novartis. Ribociclib can be used with Fulvestrant as an option for people who have hormone receptor-positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer, and who have had previous endocrine therapy.
Please register or login to comment!
Register now Login